Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.

Autor:	Eggert E; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Hillig RC; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Koehr S; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Stöckigt D; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Weiske J; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Barak N; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Mowat J; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Brumby T; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Christ CD; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Ter Laak A; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Lang T; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Fernandez-Montalvan AE; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Badock V; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Weinmann H; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Hartung IV; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Barsyte-Lovejoy D; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Szewczyk M; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Kennedy S; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Li F; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Vedadi M; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada.; Department of Pharmacology and Toxicology, University of Toronto , Toronto, Ontario M5S 1A8, Canada., Brown PJ; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Santhakumar V; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Arrowsmith CH; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada.; Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto , Toronto, Ontario M5G 2M9, Canada., Stellfeld T; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Stresemann C; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany.
Jazyk:	angličtina
Zdroj:	Journal of medicinal chemistry [J Med Chem] 2016 May 26; Vol. 59 (10), pp. 4578-600. Date of Electronic Publication: 2016 May 03.
DOI:	10.1021/acs.jmedchem.5b01890
Abstrakt:	Protein lysine methyltransferases have recently emerged as a new target class for the development of inhibitors that modulate gene transcription or signaling pathways. SET and MYND domain containing protein 2 (SMYD2) is a catalytic SET domain containing methyltransferase reported to monomethylate lysine residues on histone and nonhistone proteins. Although several studies have uncovered an important role of SMYD2 in promoting cancer by protein methylation, the biology of SMYD2 is far from being fully understood. Utilization of highly potent and selective chemical probes for target validation has emerged as a concept which circumvents possible limitations of knockdown experiments and, in particular, could result in an improved exploration of drug targets with a complex underlying biology. Here, we report the development of a potent, selective, and cell-active, substrate-competitive inhibitor of SMYD2, which is the first reported inhibitor suitable for in vivo target validation studies in rodents.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu